Cytogen, Inc.
Financials
Valuation Metrics
Cytogen, Inc.'s Market Cap is ₩767B. At end of 2025 it was ₩2079B. Ranked #1420 of 2,436 in KR market (top 58%), #804 of 1,649 on KOSDAQ (top 49%), #157 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 67%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 76.67B KRW | KR#1,420/2,436 Sec#157/234 |
| Revenue | 26.84B KRW | KR#2,066/2,436 Sec#146/234 |
| Net Income | -11.18B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 57.04B KRW | KR#2,120/2,436 Sec#188/234 |
| Net Assets | 34.11B KRW | KR#2,115/2,436 Sec#184/234 |
| Employees | 50 | KR#2,027/2,436 Sec#184/234 |
| Value | ||
| P/B | 2.25x | KR#1,996/2,436 Sec#150/234 |
| P/S | 2.86x | KR#1,996/2,436 Sec#125/234 |
| FCF Yield | -11.64% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -32.78% | KR#2,188/2,436 Sec#179/234 |
| ROA | -19.60% | KR#2,226/2,436 Sec#176/234 |
| Op. Margin | -27.08% | KR#2,168/2,436 Sec#150/234 |
| Revenue Growth | 13.98% | KR#783/2,436 Sec#69/234 |
| Financial Health | ||
| Debt Ratio | 167.22% | KR#1,403/2,436 Sec#161/234 |
| Total Debt | 14.39B KRW | KR#1,495/2,436 Sec#133/234 |
| FCF | -8.92B KRW | KR#1,673/2,436 Sec#142/234 |
| Cash | 12.98B KRW | KR#1,513/2,436 Sec#115/234 |
| Current Ratio | 3.44x | KR#526/2,436 Sec#78/234 |
| Performance | ||
| 1Y Return | 21.43% | KR#416/2,436 Sec#34/234 |
| 1M Return | 9.23% | KR#293/2,436 Sec#19/234 |
| From 52W High | -70.40% | KR#2,149/2,436 Sec#196/234 |
| 1Y MDD | -70.01% | KR#1,946/2,436 Sec#166/234 |
| Trading | ||
| Volume | 104,771 shares | KR#911/2,436 Sec#93/234 |
| Foreign Own. | 3.15% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -484 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,456 KRW | KR#2,173/2,436 Sec#190/234 |
Company Info
The company, established in 2013, is a precision medicine specialist firm with CTC-based liquid biopsy platform technology. In 2024, it diversified its business by acquiring Genome Care, a prenatal and postnatal diagnostics specialist, and now offers anti-cancer new drug development support to pharmaceutical companies, medical device distribution, and health functional food sales. Accelerating global market expansion with US and Japan subsidiaries, the company strengthens its position in the precision medicine market through technology commercialization in cooperation with major hospitals and pharmaceutical companies. Cytogen was established in 2010 and is headquartered in Songpa-gu, Seoul.